Author

Jeffrey D. Neidhart

Observed names: J. Neidhart, J.D. Neidhart, Jeffrey D Neidhart, Jeffrey Neidhart

Institution: San Juan Oncology Associates

Observed institutions: Mount Sinai Hospital, The Ohio State University Wexner Medical Center, University of Alabama at Birmingham, Highland Hospital, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Gabrail Cancer Center, San Juan Oncology Associates, Elmhurst Hospital Center, The Ohio State University, Temple University, Icahn School of Medicine at Mount Sinai

OpenAlex ID: A5038946138

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

2020 · Carlos Salama, Jian Han, et al. · New England Journal of Medicine · 1,285

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

2013 · Glen J. Weiss, Joseph Chao, et al. · Investigational New Drugs · 236

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

2018 · Judith Trotman, Sally F Barrington, et al. · The Lancet Oncology · 153

Randomized Trial of Doxorubicin, Bisantrene, and Miltoxantrone in Advanced Breast Cancer: A Southwest Oncology Group Study

1991 · J. D. Cowan, J. Neidhart, et al. · JNCI Journal of the National Cancer Institute · 76

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

2016 · Edward B Garon, Jeffrey D Neidhart, et al. · OncoTargets and Therapy · 58

Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor

2003 · Jeffrey Neidhart, Karen O. Allen, et al. · Vaccine · 55

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study

2018 · William Townsend, Christian Buske, et al. · Blood · 15

Prolonged survival after splenectomy in Wiskott-Aldrich syndrome: a case report

2011 · Kostas N Syrigos, Nektaria Makrilia, et al. · The Italian Journal of Pediatrics/Italian journal of pediatrics · 7

Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen

2022 · Jonathan Afari, Tanya M. Spektor, et al. · Experimental Hematology · 5

Abstract 1306: A Phase 1b/2a study of CRLX101, a novel nanopharmaceutical of camptothecin, in solid tumor cancer patients who have failed standard therapy

2011 · Glen Weiss, Yun Yen, et al. · Cancer Research · 4

467 Updated efficacy and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial

2010 · E.B. Garon, J. Neidhart, et al. · European Journal of Cancer Supplements · 4

Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen.

2018 · James R. Berenson, Alexa Cohen, et al. · Journal of Clinical Oncology · 2

Abstract A97: Final phase 1/2a results evaluating the cyclodextrin-containing nanoparticle CRLX101 in patients with advanced solid tumor malignancies.

2011 · Yun Yen, Lori A. Coerver, et al. · Molecular Cancer Therapeutics · 1

Achieving epidemiologically representative enrollment and social determinants of health in the phase III evERA Breast Cancer study (NCT05306340).

2026 · Gregory A. Vidal, Hope S. Rugo, et al. · Journal of Clinical Oncology

B-F1RST: Assessment of novel blood-based biomarkers in patients with first-line advanced or metastatic NSCLC receiving atezolizumab monotherapy.

2017 · Edward S. Kim, Mark A. Socinski, et al. · Journal of Clinical Oncology

Analysis of efficacy and safety of POM as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma pts refractory to a lenalidomide-containing combination regimen.

2017 · James R. Berenson, Alexa Cohen, et al. · Journal of Clinical Oncology

Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer

2005 · Pierre L. Triozzi, Graeme B. Bolger, et al. · The Prostate

Works count: 18

Citation count: 1,905

H-index: 7

I10-index: 7